Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Guru Sonpavde MD

Guru P. Sonpavde MD

Genitourinary Oncology Director, Christopher K. Glanz Chair for Bladder Cancer Research, Assistant Director Phase I Clinical Research Unit, AdventHealth Cancer Institute, Orlando, Florida

Dr. Guru Sonpavde, MD, is the Genitourinary Oncology Director at the AdventHealth Cancer Institute and the Christopher K. Glanz Chair for Bladder Cancer Research. He completed his fellowship in medical oncology and hematology at Indiana University. He leads multiple cutting-edge clinical trials studying novel immunotherapy and targeted drugs to treat urological cancers, particularly bladder cancer. He is the national or international principal investigator on multiple clinical trials for bladder cancer. He has also led translational projects and developed prognostic classifications and clinical endpoints focused on bladder cancer. He is a member of Southwest Oncology Group (SWOG) and the Bladder Cancer Task Force of the National Cancer Institute Genitourinary Cancers Steering Committee.

Disclosures

Dr. Sonpavde reports the following:

  • Advisory Board: BMS, Genentech, EMD Serono, Merck, Sanofi, Seattle Genetics/Astellas, Astrazeneca, Exelixis, Janssen, Bicycle Therapeutics, Pfizer, Gilead, Scholar Rock, G1 Therapeutics, Eli Lilly/Loxo Oncology, Infinity Pharmaceuticals, Lucence Health, IMV

  • Research Support: Sanofi (iaward), Astrazeneca, Gilead, Helsinn, Lucence, Predicine, BMS, EMD Serono, Jazz Therapeutics, Genecentric, Kure it, NCI (R21)

  • Steering committee of studies: BMS, Bavarian Nordic, Seattle Genetics, QED, G1 Therapeutics (all unpaid), and Astrazeneca, EMD Serono, Debiopharm (paid)
  • Data safety monitoring committee: Mereo
  • Employment: Spouse employed by Myriad
  • Writing/Editor fees: Uptodate, Editor of Elsevier Practice Update Bladder Cancer Center of Excellence
  • Speaking fees: Physicians Education Resource (PER), Onclive, Research to Practice, Medscape, Cancer Network, Masters Lecture Series (MLS)

Recent Contributions to PracticeUpdate:

  1. ASCO 2023: Abstract Recommendations From Dr. Guru Sonpavde for Bladder Cancer
  2. 2022 Top Story in Bladder Cancer: Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer
  3. Any Regression of Tumor (ART) as a Potential Intermediate Endpoint in Patients With Solid Tumors Receiving ICIs
  4. Searching Out Baseline Variables Associated With Response to PD-L1 Inhibition in Patients With Metastatic Urothelial Carcinoma Progressing After Chemotherapy
  5. JAVELIN Bladder 100: Genomic Biomarker Analysis of a Study of Maintenance Avelumab for Advanced Urothelial Carcinoma
  6. PD-L1 Expression and Outcomes With Atezolizumab Among Patients With Metastatic Urothelial Cancer
  7. BladderPath: MRI vs Cystoscopic Staging for Newly Diagnosed Bladder Cancer
  8. RACE IT: Preoperative Radiation Therapy Combined With Immunotherapy in Locally Advanced Urothelial Carcinoma
  9. Study EV-103 Cohort K: Enfortumab Vedotin Alone or in Combination With Pembrolizumab for Advanced Urothelial Carcinoma
  10. Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer

Elsewhere

Recently Updated